Phenylalkylaminoalcohol carbamates and process for preparing the same
    22.
    发明授权
    Phenylalkylaminoalcohol carbamates and process for preparing the same 失效
    苯基烷基氨基醇氨基甲酸酯及其制备方法

    公开(公告)号:US5955499A

    公开(公告)日:1999-09-21

    申请号:US619657

    申请日:1996-07-01

    CPC分类号: C07C271/12 Y02P20/55

    摘要: O-carbamoyl-(D/L )-phenylalaninol represented by structural formula I is pharmaceutically useful to treat diseases of the central nervous system, which is prepared by a characteristic process comprising the steps of: treating phenylalaninol with benzyl chloroformate in a basic aqueous solution medium, to give N-benzyloxycarbonyl-phenylalaninol; subjecting this intermediate to reaction with phosgene and then, to the treatment with excess of concentrated ammonium hydroxide aqueous solution, to provide O-carbamoyl-N-benzyloxycarbonyl-phenylalaninol; deprotecting it through hydrogenolysis reaction. ##STR1##

    摘要翻译: PCT No.PCT / KR95 / 00114 Sec。 371日期:1996年7月1日 102(e)日期1996年7月1日PCT提交1995年9月6日PCT公布。 公开号WO96 / 07637 日期:1996年3月14日由结构式I表示的O-氨基甲酰基 - (D / L) - 苯丙氨醇在药学上可用于治疗中枢神经系统疾病,其通过特征性方法制备,包括以下步骤:用氯甲酸苄酯处理苯丙氨醇 在碱性水溶液介质中,得到N-苄氧羰基 - 苯基丙氨醇; 使该中间体与光气反应,然后用过量的浓氢氧化铵水溶液处理,得到O-氨基甲酰基-N-苄氧羰基 - 苯丙氨酸; 通过氢解反应脱保护。

    Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
    23.
    发明授权
    Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol 失效
    来自2-苯基-1,2-乙二醇的卤素取代的氨基甲酸酯化合物

    公开(公告)号:US5698588A

    公开(公告)日:1997-12-16

    申请号:US586497

    申请日:1996-01-16

    摘要: The pure enantiomeric forms, as well as enantiomeric mixtures excluding the racemic mixture of monocarbamates of 2-phenyl-1,2-ethanediol substituted with more than one halogen atom on the phenyl ring and dicarbamates of 2-phenyl-1,2-ethanediol substituted with more than one halogen atom on the phenyl ring have been found to be effective in the treatment of disorders of the central nervous system.

    摘要翻译: 纯对映异构体形式,以及除苯基环上被一个以上卤素原子取代的2-苯基-1,2-乙二醇的单体氨基甲酸酯的外消旋混合物和2-苯基-1,2-乙二醇取代的二异氰酸酯的对映体混合物 已经发现苯环上多于一个的卤素原子在治疗中枢神经系统紊乱中是有效的。

    Transnasal anticonvulsive compositions and modulated process
    26.
    发明授权
    Transnasal anticonvulsive compositions and modulated process 失效
    经鼻抗惊厥组合物和调节过程

    公开(公告)号:US07132112B2

    公开(公告)日:2006-11-07

    申请号:US10634689

    申请日:2003-08-05

    IPC分类号: A61F13/00 A61L9/04

    摘要: A novel method of vehicle modulated administration of an anticonvulsive agent to the mucous membranes of humans and animals is disclosed. The vehicle system is an aqueous pharmaceutical carrier comprising an aliphatic alcohol (10–80%) or a glycol (10–80%), and their combinations with a biological surfactant such as a bile salt or a lecithin. The pharmaceutical composition provides a means to control and promote the rate and extent of transmucosal permeation and absorption of the medicaments via a single and multiple administration. Nasal administration of the pharmaceutical preparation produces a high plasma concentration of the anticonvulsant nearly as fast as intravenous administration. Such compositions are particularly suitable for a prompt and timely medication of patients in the acute and/or emergency treatment of status epilepticus and other fever-induced seizures.

    摘要翻译: 公开了一种抗人惊厥剂对人和动物粘膜的车辆调节施用的新方法。 载体系统是包含脂族醇(10-80%)或二醇(10-80%))及其与生物表面活性剂如胆汁盐或卵磷脂的组合的水性药物载体。 药物组合物通过单次和多次施用提供控制和促进药物经粘膜渗透和吸收的速率和程度的手段。 药物制剂的鼻内给药几乎与静脉内施用一样快地产生抗惊厥药的高血浆浓度。 这种组合物特别适用于急性和/或紧急治疗癫痫持续状态和其他发热引起的发作的患者的及时和及时的药物。

    Carbamate compounds for use in preventing or treating bipolar disorder
    27.
    发明授权
    Carbamate compounds for use in preventing or treating bipolar disorder 失效
    用于预防或治疗双相情感障碍的氨基甲酸酯化合物

    公开(公告)号:US07122576B2

    公开(公告)日:2006-10-17

    申请号:US10081606

    申请日:2002-02-21

    IPC分类号: A01N47/10 A61K31/27

    CPC分类号: A61K31/27

    摘要: This invention is directed to a method for preventing or treating bipolar disorder comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) or enantiomeric mixture wherein one enantiomer of Formula (I) predominates: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen and C1–C4 alkyl; wherein C1–C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1–C4 alkyl, C1–C4 alkoxy, amino, nitro and cyano).

    摘要翻译: 本发明涉及一种预防或治疗双相性精神障碍的方法,包括向有需要的受试者施用治疗有效量的式(I)的对映异构体或其对映体混合物,其中式(I)的一个对映异构体占优势:其中苯基被取代 在X处具有选自氟,氯,溴和碘的一至五个卤素原子; 且R 1,R 2,R 3和R 4各自独立地选自氢 和C 1 -C 4烷基; 其中C 1 -C 4烷基任选被苯基取代(其中苯基任选被独立地选自卤素,C 1 -C 4烷基的取代基取代, C 1 -C 4烷基,C 1 -C 4烷氧基,氨基,硝基和氰基)。